Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer

Area of Science:

• Oncology
• Neuroscience
• Psychology

Background:

• Adjuvant chemotherapy for breast cancer is associated with neurocognitive deficits.
• Cyclophosphamide/methotrexate/5-fluorouracil (CMF) is a common chemotherapy regimen.
• Understanding long-term cognitive effects is crucial for patient care.

Purpose of the Study:

• To evaluate persistent neurocognitive problems in breast cancer patients treated with CMF.
• To integrate neuropsychological and electrophysiological data for a comprehensive assessment.
• To compare outcomes at different time points post-treatment.

Main Methods:

• Neuropsychological testing was performed 1 year post-CMF treatment (T1) in 63 patients and 60 controls.
• Patients were classified as cognitively impaired or unimpaired at T1.
• Behavioral and neurophysiological measures were assessed 4 years later (T2) in a subgroup (n=26).
• Cognitively impaired patients (T1) were compared with unimpaired patients (T1) at T2.

Main Results:

• 33.3% of CMF-treated patients showed cognitive impairment at T1, versus 10% of controls.
• At T2, impaired patients exhibited longer P3 latencies and lower P3 amplitudes.
• Impaired patients also demonstrated longer reaction times and increased errors in information processing tasks.

Conclusions:

• Neurocognitive deficits persist for at least 5 years after CMF chemotherapy completion.
• Findings are consistent across both neuropsychological and electrophysiological assessments.
• This highlights the need for long-term monitoring and supportive care for cancer survivors.